Regen BioPharma Inc (RGBP)

[OTCShotCaller]

Regarding Recent FDA Approval - Commencement of Clinical Trials

...the first step toward globalization of RGBP's NR2F6 Patent for treating pancreatic & colon cancer.

KCL Therapeutics, Inc.(“KCL”), a wholly owned subsidiary of Regen Biopharma Inc (the “Company”), was informed by the United States Patent & Trademark Office (USPTO) that Patent Protection shall be granted to KCL with regard to “Methods and means of generating IL-17 associated anti-tumor effector cells by NR2F6 inhibition.

Chairman/CEO David Koos noted:

#1- "Checkpoint inhibitors are a new class of drugs that include Ipilimumab (Yervoy® Bristol Myers Squibb; 2018 estimated sales of $1.5 Billion1), and Pembrolizumab (Keytruda® Merck, 2017 sales of $3.4 Billion."

#2- "Current checkpoint inhibitors act to augment immune responses but do not have direct anticancer effects."

#3- "By creating approaches to inhibit NR2F6 the Company aims to develop a new class of Checkpoint Inhibitors that concurrently block tumor growth while enhancing the immune system."

F.Y.I. YOU'RE WITNESSING THE FUTURE OF MEDICINE IN PROGRESS VIA THIS SINGLE MULTI-BILLION DOLLAR MARKET CAPACITY PATENT OF WHICH RGBP HAS MANY!!! (20+)

Be well and prosper...